BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38415537)

  • 21. Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis.
    Durko L; Wlodarski W; Stasikowska-Kanicka O; Wagrowska-Danilewicz M; Danilewicz M; Hogendorf P; Strzelczyk J; Malecka-Panas E
    Dis Markers; 2017; 2017():3276806. PubMed ID: 28659655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of CD44+CD24+ gastric cancer stem cells.
    Zhang C; Li C; He F; Cai Y; Yang H
    J Cancer Res Clin Oncol; 2011 Nov; 137(11):1679-86. PubMed ID: 21882047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma.
    Lin Y; Zhong Y; Guan H; Zhang X; Sun Q
    J Exp Clin Cancer Res; 2012 Jul; 31(1):59. PubMed ID: 22762532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics.
    Wei X; Dombkowski D; Meirelles K; Pieretti-Vanmarcke R; Szotek PP; Chang HL; Preffer FI; Mueller PR; Teixeira J; MacLaughlin DT; Donahoe PK
    Proc Natl Acad Sci U S A; 2010 Nov; 107(44):18874-9. PubMed ID: 20952655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Study on the correlation factors on CD44+ CD24-/low ESA+ Lin- cell ratio in breast cancer].
    Wang R; Yang XQ; Lü Q
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jan; 45(1):53-6. PubMed ID: 24527582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma.
    Choi D; Lee HW; Hur KY; Kim JJ; Park GS; Jang SH; Song YS; Jang KS; Paik SS
    World J Gastroenterol; 2009 May; 15(18):2258-64. PubMed ID: 19437567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD24+CD44+CD54+EpCAM+ gastric cancer stem cells predict tumor progression and metastasis: clinical and experimental evidence.
    Gómez-Gallegos AA; Ramírez-Vidal L; Becerril-Rico J; Pérez-Islas E; Hernandez-Peralta ZJ; Toledo-Guzmán ME; García-Carrancá A; Langley E; Hernández-Guerrero A; López-Casillas F; Herrera-Goepfert R; Oñate-Ocaña LF; Ortiz-Sánchez E
    Stem Cell Res Ther; 2023 Feb; 14(1):16. PubMed ID: 36737794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of human breast cancer CD44
    Qiao X; Zhang Y; Sun L; Ma Q; Yang J; Ai L; Xue J; Chen G; Zhang H; Ji C; Gu X; Lei H; Yang Y; Liu C
    Elife; 2021 Jul; 10():. PubMed ID: 34318746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
    Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
    J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Significance of
    Strati A; Nikolaou M; Georgoulias V; Lianidou ES
    Cells; 2019 Jun; 8(7):. PubMed ID: 31261917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
    Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
    Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of CD44+/CD24-/low biomarker for screening, diagnosis and monitoring of breast cancer.
    Camerlingo R; Ferraro GA; De Francesco F; Romano M; Nicoletti G; Di Bonito M; Rinaldo M; D'Andrea F; Pirozzi G
    Oncol Rep; 2014 Mar; 31(3):1127-32. PubMed ID: 24366074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD44+/CD24- breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties.
    Sun H; Jia J; Wang X; Ma B; Di L; Song G; Ren J
    Clin Transl Oncol; 2013 Jan; 15(1):46-54. PubMed ID: 22855175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer.
    Liu M; Mor G; Cheng H; Xiang X; Hui P; Rutherford T; Yin G; Rimm DL; Holmberg J; Alvero A; Silasi DA
    Reprod Sci; 2013 May; 20(5):605-15. PubMed ID: 23171677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epithelial-mesenchymal transition and cancer stem cell interactions in breast phyllodes tumours: immunohistochemical evaluation of EZH2, EZR, HMGA2, CD24 and CD44 in correlation with outcome analysis.
    Ahmed SS; Lim JCT; Thike AA; Iqbal J; Tan PH
    J Clin Pathol; 2022 May; 75(5):316-323. PubMed ID: 33627375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.
    Duru N; Fan M; Candas D; Menaa C; Liu HC; Nantajit D; Wen Y; Xiao K; Eldridge A; Chromy BA; Li S; Spitz DR; Lam KS; Wicha MS; Li JJ
    Clin Cancer Res; 2012 Dec; 18(24):6634-47. PubMed ID: 23091114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
    Bane A; Viloria-Petit A; Pinnaduwage D; Mulligan AM; O'Malley FP; Andrulis IL
    Breast Cancer Res Treat; 2013 Jul; 140(1):195-205. PubMed ID: 23813303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.
    Adamczyk A; Niemiec JA; Ambicka A; Mucha-Małecka A; Mituś J; Ryś J
    J Mol Histol; 2014 Feb; 45(1):35-45. PubMed ID: 23835592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognosis assessment of CD44
    Gu J; Chen D; Li Z; Yang Y; Ma Z; Huang G
    Arch Gynecol Obstet; 2022 Oct; 306(4):1147-1160. PubMed ID: 35435483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.